Mode
Text Size
Log in / Sign up

JSLE linked to higher CVD risk factors than JDM in adults with childhood-onset autoimmune diseases

JSLE linked to higher CVD risk factors than JDM in adults with childhood-onset autoimmune diseases
Photo by Logan Voss / Unsplash
Key Takeaway
Consider higher CVD risk factors in JSLE vs. JDM adults from childhood-onset disease.

This single-centre longitudinal cohort study compared adults with childhood-onset juvenile systemic lupus erythematosus (JSLE, n=76) and juvenile dermatomyositis (JDM, n=79), with mean follow-up of 10.0 ± 4.2 years for JSLE and 11.0 ± 5.1 years for JDM. The JSLE cohort was older at assessment (mean age 24.3 ± 4.2 years vs. 20.1 ± 5.0 years for JDM, p<0.001), but follow-up duration did not differ significantly (p=0.68). JSLE showed higher prevalence of hypertension (p=0.02) and dyslipidaemia (p=0.0005), and higher total cholesterol (p=0.01) and LDL-cholesterol levels (p=0.02) compared to JDM. Damage accumulation was not significantly different between cohorts (JSLE: 39/76 or 51.3%, JDM: 47/79 or 59.4%, p=0.307), but body mass index independently predicted damage in both (JSLE: p=0.038, JDM: p=0.026). The PDAY score for cardiovascular disease (CVD)-risk stratification was higher in JSLE (median 5 points, range 4-13) than JDM (median 0 points, range 0-3, p=0.0001), though adult CVD-risk scores were very low in both. Safety and tolerability were not reported. Key limitations include the observational design, which shows associations not causation, and the single-centre setting, which may limit generalizability. Practice relevance is not reported, but clinicians should note these findings as preliminary evidence from a specific cohort, requiring confirmation in larger, multi-centre studies.

Study Details

Study typeCohort
Sample sizen = 76
EvidenceLevel 3
PublishedApr 2026
View Original Abstract ↓
Objectives: Juvenile systemic lupus erythematosus (JSLE) and juvenile dermatomyositis (JDM) are systemic autoimmune rheumatic diseases (RMDs) with childhood-onset associated with increased risk of damage accumulation and cardiovascular disease (CVD) over the life course. Methods: Damage associated with JSLE and JDM has been assessed using validated outcome measures in a longitudinal single-centre cohort study with long-term follow-up, involving data collected both retrospectively and prospectively. Descriptive statistics, sensitivity and regression analyses have been used to evaluate predictors of damage and CVD-risk. Results: We assessed comparatively a JSLE cohort (n=76), with a mean age of 24.3 +/- 4.2 years and a JDM cohort (n=79) with a mean 20.1 +/-5.0 years (p<0.001), with matched duration of follow-up (10.0 +/- 4.2 vs. 11.0 +/- 5.1, respectively, p=0.68). Traditional CVD-risk factors, including hypertension (p=0.02), dyslipidaemia (p=0.0005), and higher total cholesterol (p=0.01) and LDL-cholesterol (p=0.02) levels at the last assessment were higher in JSLE vs. JDM. Over the disease course, 39 (51.3%) AYA with JSLE vs. 47 (59.4%) AYA with JDM accumulated damage (p=0.307), which was independently predicted by the body mass index in both cohorts (p=0.038 and p=0.026, respectively). The PDAY score was the only tool able to stratify AYA based on CVD-risk (median = 5 (4-13) points in JSLE vs. 0 (0-3) points in JDM, p=0.0001), as all the adult CVD-risk scores were very low in both cohorts. Conclusions: This is the first comparative evaluation of JSLE vs. JDM in adulthood, which highlighted increased damage burden and CVD-risk in JSLE that warrants further investigation.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.